Pharmacokinetic Optimisation of Treatment Schedules for Anthracyclines and Paclitaxel in Patients with Cancer

[1]  O. Garrone,et al.  Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Amadori,et al.  Schedule‐dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines , 1999, International journal of cancer.

[3]  G. Sledge,et al.  Taxanes in the treatment of breast cancer: a prodigy comes of age. , 1999, Cancer investigation.

[4]  D. Cohen,et al.  The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[5]  N. Dobbs,et al.  Doxorubicin pharmacokinetics: the effect of abnormal liver biochemistry tests , 1998, Cancer Chemotherapy and Pharmacology.

[6]  M. Berger,et al.  Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Davey,et al.  Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel , 1998, International journal of cancer.

[8]  G. Rosner,et al.  Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Wiseman,et al.  Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. , 1998, Drugs & aging.

[10]  H. Kim,et al.  Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  W. Evans,et al.  Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. , 1998, Clinical chemistry.

[12]  M. Zucchetti,et al.  Pharmacokinetics of anticancer agents in patients with impaired liver function. , 1998, European journal of cancer.

[13]  C. Hudis,et al.  Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel. , 1998, Cancer investigation.

[14]  B. Eletti,et al.  Greater antitumor efficacy of paclitaxel administered before epirubicin in a mouse mammary carcinoma , 1998, Journal of Cancer Research and Clinical Oncology.

[15]  S. Baker,et al.  Drug Interactions with the Taxanes , 1997, Pharmacotherapy.

[16]  J. Beijnen,et al.  Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. , 1997, Seminars in oncology.

[17]  M. Bibby,et al.  Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids. , 1997, European journal of cancer.

[18]  C. Tibaldi,et al.  Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Bonadonna,et al.  Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Faulds,et al.  Epirubicin , 1997, Drugs.

[21]  B. Monsarrat,et al.  Biotransformation of taxoids by human cytochromes P450: structure-activity relationship. , 1997, Bulletin du cancer.

[22]  G. Hortobagyi,et al.  Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer. , 1997, Seminars in oncology.

[23]  G. Giaccone,et al.  Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Decorti,et al.  Adriamycin-induced histamine release from heart tissue in vitro , 1997, Cancer Chemotherapy and Pharmacology.

[25]  B. Sikic,et al.  Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein , 1997, Cancer Chemotherapy and Pharmacology.

[26]  M. Davey,et al.  Extended multidrug resistance in haemopoietic cells , 1996, British journal of haematology.

[27]  G. Hortobagyi,et al.  Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M D'Incalci,et al.  Paclitaxel induces significant changes in epidoxorubicin distribution in mice. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  J. Beijnen,et al.  Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. , 1996, Cancer research.

[30]  G. de Sousa,et al.  Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. , 1996, Cancer research.

[31]  F. Ognibene,et al.  Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Gehl,et al.  Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer. , 1996, Seminars in oncology.

[33]  D. Amadori,et al.  A Phase I/II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer. , 1996, Seminars in oncology.

[34]  M. Millward,et al.  Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. , 1996, British Journal of Cancer.

[35]  B. Monsarrat,et al.  Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. , 1996, Cancer research.

[36]  Y. Miura,et al.  Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro. , 1995, European journal of cancer.

[37]  M. Relling,et al.  Variability in human cytochrome P450 paclitaxel metabolism. , 1995, The Journal of pharmacology and experimental therapeutics.

[38]  A. Caraceni,et al.  Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  H. Rosing,et al.  Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  R. Danesi,et al.  Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. , 1995, Molecular pharmacology.

[41]  A. Cavaliere,et al.  Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity. , 1995, The Journal of clinical investigation.

[42]  T. Lampidis,et al.  Antiproliferative activity of taxol on human tumor and normal breast cells vs. effects on cardiac cells , 1995, International journal of cancer.

[43]  G. Bonadonna,et al.  Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  K. Korzekwa,et al.  Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. , 1994, Cancer research.

[45]  G. Giaccone,et al.  Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol). , 1994, Seminars in oncology.

[46]  F. Guengerich,et al.  Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. , 1994, Cancer research.

[47]  B. Sikic,et al.  Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  T. Walle,et al.  Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. , 1994, The Journal of pharmacology and experimental therapeutics.

[49]  K. Cowan,et al.  Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. , 1994, Journal of the National Cancer Institute.

[50]  B. Monsarrat,et al.  Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. , 1994, Cancer research.

[51]  R. Olson,et al.  Time‐related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function , 1993, British journal of pharmacology.

[52]  James B. Mitchell,et al.  Taxol in combination with doxorubicin or etoposide possible antagonism in vitro , 1993, Cancer.

[53]  James B. Mitchell,et al.  Taxol in Combination with Doxorubicin or Etoposide , 1993 .

[54]  B. Monsarrat,et al.  Hepatic metabolism and biliary excretion of Taxol in rats and humans. , 1993, Journal of the National Cancer Institute. Monographs.

[55]  N. Dobbs,et al.  Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests. , 1992, British Journal of Cancer.